Questions with a common theme will be selected and answered comprehensively
by our Distinguished Faculty members. Previously answered questions will be
archived for your reference. If you wish to submit a question, click here.

To view archived responses, click here.
Question Archive


You may view the responses to previous questions submitted on this site below by clicking on the associated question. The most recent responses appear first.

Question 15 (Response by Shehzad S. Basaria, MD, and Edward D. Kim, MD): posted 2/24/10
The relationship between testosterone levels and cardiovascular disease (CVD) has not been fully elucidated, and concerns persist. What is the relationship between hypogonadism and CVD, and what implications does that relationship present regarding screening for and treating hypogonadism and future research?


Question 14 (Response by Andre T. Guay, MD, and Abdulmaged M. Traish, MBA, PhD): posted 1/26/10
Metabolic syndrome, characterized by a group of risk factors that include abdominal obesity, dyslipidemia, hypertension, and insulin resistance, is a growing health concern. What is the relationship between metabolic syndrome and hypogonadism, and why is it imperative to screen for and treat both conditions?


Question 13 (Response by Richard Sadovsky, MD, and Abraham Morgentaler, MD): posted 8/27/09
A number of testosterone formulations are available to treat male hypogonadism. How do long-acting testosterone formulations affect the treatment of this condition in male hypogonadal patients with differing needs and considerations?


Question 12 (Response by Allen D. Seftel, MD, and Wayne J.G. Hellstrom, MD): posted 5/29/09
The main goals of testosterone therapy are to achieve constant eugonadal testosterone levels and relieve symptoms of hypogonadism for male patients. How do the differentiating properties of each testosterone formulation affect the patient’s therapy choice and optimize outcomes?


Question 11 (Response by Ronald S. Swerdloff, MD, and Robert S. Tan, MD): posted 4/20/09
Hypogonadism is a serious chronic condition associated with chronic comorbidities. What considerations would affect a patient’s long-term adherence to and persistence with testosterone therapy?


Question 10 (Response by Leonard S. Marks, MD, and E. David Crawford, MD): posted 2/27/09
A causal link between testosterone therapy and prostate cancer has not been established. What are the implications of long-term testosterone treatment for male patients with hypogonadism?


Question 9 (Response by Christina Wang, MD): posted 1/09/09
What effects do the various chronic testosterone therapies have on serum testosterone levels?


Question 8 (Response by Adrian S. Dobs, MD): posted 11/04/08
What is the relationship between low testosterone levels and elevated estradiol levels in obese men? What is the impact of elevated estradiol?


Question 7 (Response by Wayne J.G. Hellstrom, MD): posted 06/02/08
Hypogonadism is a chronic clinical condition. What are the potential harms when a patient does not adhere to a regimen of chronic testosterone therapy?


Question 6 (Response by Martin Miner, MD): posted 03/15/08
How do injectable and transdermal testosterone therapies for hypogonadism impact associated psychological symptoms?


Question 5 (Response by Richard Sadovsky, MD): posted 12/15/07
What is the association between obesity and hypogonadism? How will testosterone therapy benefit obese hypogonadal patients?


Question 4 (Response by Frances Hayes, MD): posted 11/15/07
Which factors affect patient adherence with testosterone therapy? How can clinicians promote adherence?


Question 3 (Response by Allen D. Seftel, MD): posted 09/15/07
What is the ideal testosterone therapy for treating patients with hypogonadism?


Question 2 (Response by Abraham Morgentaler, MD): posted 08/15/07
What steps should be taken before and during testosterone therapy to ensure prostate health?


Question 1 (Response by Ridwan Shabsigh, MD): posted 07/05/07
How does testosterone therapy affect cardiovascular risk?


back to top